Notice: This company has been marked as potentially delisted and may not be actively trading. Clarus Therapeutics (CRXTW) News Today Add Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period ANTX AN2 Therapeutics, Inc.March 26, 2024 | seekingalpha.comClarus Corp.April 5, 2023 | wsj.comClarus Therapeutics Holdings, Inc. (CRXWQ)March 24, 2023 | ca.finance.yahoo.comEarnings Preview For ClarusFebruary 26, 2023 | msn.comCRXTQ Clarus Therapeutics Holdings, Inc.January 21, 2023 | seekingalpha.comClarus Therapeutics Holdings, Inc. (CRXTQ)November 18, 2022 | ca.finance.yahoo.comClarus Therapeutics Hldgs Stock (OTC:CRXTQ), Guidance and ForecastSeptember 26, 2022 | benzinga.comFirm Retention Summary: Clarus Therapeutics Holdings Inc.September 16, 2022 | wsj.comClarus files for chapter 11 bankruptcy, eyes auction of testosterone therapy JatenzoSeptember 7, 2022 | seekingalpha.comWhy Clarus Corp. Stock Plummeted on MondayAugust 29, 2022 | nasdaq.comClarus Board of Directors Approves Two of Its Top Shareholders to Increase Their Positions up to 12.5% of Shares OutstandingAugust 22, 2022 | finance.yahoo.comClarus Therapeutics Cuts Staff, Evaluates Strategic AlternativesAugust 18, 2022 | marketwatch.comClarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce ReductionAugust 18, 2022 | finance.yahoo.com Get Clarus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRXTW and its competitors with MarketBeat's FREE daily newsletter. Email Address CRXTW Media Mentions By Week CRXTW Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRXTW News Sentiment▼0.000.27▲Average News Sentiment CRXTW News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRXTW Articles This Week▼00▲CRXTW Articles Average Week Get Clarus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRXTW and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRXTW) was last updated on 2/5/2025 by MarketBeat.com Staff From Our PartnersNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNew crypto boom will be greatest in historyUrgent Notice from Ian King, the Crypto Expert Who Made 18,325% in a Year: “Donald Trump’s second term is t...Banyan Hill Publishing | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clarus Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clarus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
